Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing – Sanofi and Existing Investor,

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial – ZONE study to evaluate the effect of ZT-01 on

– Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in

– First patient dosing expected in Q3 2023 – – ZONE study to assess ZT-01’s ability to prevent night-time hypoglycemia,

– Achieves development milestones required to complete Series A financing – – Plans to file Phase 2 investigational new drug

– Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – –

Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01 – Second grants from GlycoNet and

Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes – ZT-01

Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01 – Proof-of-Concept Trial to Evaluate the Effect of ZT-01

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 –